What's Happening?
New research indicates that depriving tumors of nicotinic acid (NA) can make nicotinate phosphoribosyltransferase (NAPRT)-expressing tumors more susceptible to nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, a class of promising anticancer
agents. NAMPT inhibitors typically target NAD+ biosynthesis from nicotinamide (NAM). However, their effectiveness is often limited in tumors that also express NAPRT, which can produce NAD+ from NA. The study, published in Nature's Signal Transduction and Targeted Therapy, found that in vitro, the absence of NA from culture medium sensitized various NAPRT-expressing cancer cells (ovarian, pancreatic, breast, colorectal) to the NAMPT inhibitor FK866. This NA-mediated rescue effect was specific to NAPRT-expressing cells. In vivo experiments using mouse xenografts showed that an NA-free diet (NAFD) combined with FK866 effectively reduced tumor growth and intratumoral NAD+ levels in NAPRT-expressing ovarian cancer models. This combined approach also proved effective in an immunocompetent mouse model of breast cancer.
Why It's Important?
This discovery holds significant importance for cancer treatment, particularly for patients with NAPRT-expressing tumors, which include a substantial percentage of ovarian, breast, pancreatic, head & neck, liver, esophageal, and prostate cancers. High NAPRT expression is associated with poor survival outcomes, underscoring the urgent need for effective therapeutic strategies. Current NAPRT inhibitors have limitations in potency and solubility. The finding that dietary restriction of NA can sensitize these tumors to existing NAMPT inhibitors offers a novel and potentially more accessible therapeutic approach. By targeting the NAD+ biosynthesis pathway through both pharmacological inhibition and dietary intervention, this strategy could overcome resistance mechanisms and improve treatment efficacy for a challenging subset of cancers. It also highlights the critical role of nutrient availability in cancer metabolism and treatment response.
What's Next?
The research suggests that clinical studies combining NA-free diets with NAMPT inhibitors in cancer patients should be pursued. These studies should utilize NAPRT as an efficacy biomarker and assess whether tumor NAPRT or NAD+ content levels might limit the benefits of this approach. To minimize potential adverse events associated with systemic NAD+ depletion, future strategies could involve combining NA-free diets with NAMPT-targeting agents that selectively inhibit tumor NAD+ production. Further investigation is also needed to understand the full impact of NA-free diets on systemic NAD+ levels and to ensure patient safety and tolerability. The potential for dietary interventions to enhance chemotherapy efficacy opens a new avenue for integrated cancer care.
Beyond the Headlines
This research delves into the intricate metabolic dependencies of cancer cells, revealing how specific nutrient pathways can be exploited for therapeutic gain. The concept of "nicotinic acid starvation" as a sensitizing agent underscores the growing field of nutritional oncology, where dietary modifications are explored as adjuncts to conventional cancer treatments. This approach could lead to personalized dietary recommendations for cancer patients, tailored to the metabolic profiles of their tumors. Furthermore, the study's findings about the role of mycoplasma contamination in conferring resistance to FK866 by producing NA from NAM highlight the complex interplay between the tumor microenvironment, microbial presence, and treatment outcomes. This suggests that controlling microbial factors could also be a crucial, albeit less obvious, aspect of optimizing cancer therapies. The ethical implications of strict dietary regimens in cancer patients, including potential nutritional deficiencies, would need careful consideration in clinical translation.
